The endothelin axis, composed of two G-protein-coupled receptors, ETA and ETB, and three ligands, ET-1, −2, and −3, is involved in many physiological functions.1 The deregulation of this axis is associated with a large variety of diseases.2,3 In a tumor context, several studies have demonstrated that the ETA and ETB signaling pathways are involved in several hallmarks of tumor progression.2,4,5 Thus, endothelin receptors have become a major target for cancer treatment as illustrated by numerous clinical trials (NCT04205227, NCT04158635, NCT05072106).6–8. The gene discussed is EDN1; the disease is neoplasm.